SCHEMBL10060112

SCHEMBL10060112

Cn1ncc(-c2nc(-c3cccc(S(N)(=O)=O)c3)co2)c1CCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
CA9 Q16790 7/20 0.36
CA12 O43570 5/20 0.36
CA1 P00915 5/20 0.36
CA2 P00918 5/20 0.36
TRPV1 Q8NER1 1/20 0.35
PTGDR Q13258 1/20 0.35
HSD11B1 P28845 1/20 0.35
KDR P35968 1/20 0.35
EPHB4 P54760 1/20 0.35
TEK Q02763 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10058843 0.90 S1PR1 (0.41) ADRB2ADRB1ADRB3S1PR1S1PR3
SCHEMBL14972931 0.86 CA9 (0.48) S1PR1CA9CA12CA1CA2
SCHEMBL10058483 0.85 CA1 (0.47) CA9CA1CA2
SCHEMBL10060160 0.84 CA9 (0.47) S1PR1CA9CA12CA1CA2
SCHEMBL14973305 0.82 TRPV1 (0.37) CA9CA12CA1CA2TRPV1
SCHEMBL14973212 0.80 CA9 (0.37) CA9CA12CA1CA2KDR
SCHEMBL14973028 0.77 S1PR1 (0.41) S1PR1CA9CA12CA1CA2
SCHEMBL14973089 0.77 POLB (0.46) S1PR1CA9CA12CA1CA2
SCHEMBL10060110 0.76 CA2 (0.45) CA1CA2PTGS2
SCHEMBL14973225 0.76 MAOA (0.37) CA9CA12CA1CA2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
WO-2012020820-A1 HETEROARYL-PYRAZOLE DERIVATIVE 大正製薬株式会社 (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A ADRB2 157/4885ADRB1 212/4885ADRB3 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.